Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed PDUFA date

Bristol Myers Squibb laid out some big plans over the last couple of years for its Celgene-acquired anemia drug Reblozyl, forecasting a $4 billion-plus peak sales estimate on the back of several potential label expansions.